<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48685">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022228</url>
  </required_header>
  <id_info>
    <org_study_id>Dual Trigger</org_study_id>
    <nct_id>NCT02022228</nct_id>
  </id_info>
  <brief_title>Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome</brief_title>
  <official_title>Dual Trigger With GnRH Agonist and Human Chorionic Gonadotropin for Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chenshiling</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comprehensive Strategic Sciences Cooperation Projects of Guangdong Province and Chinese Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Science and Technology Program key projects</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Key Basic Research Development Plan of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte
      maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian
      hyperstimulation syndrome (OHSS) in high-risk patients.

      However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH)
      level post trigger with single injection of GnRH agonist, which might be related to the
      shorter duration and lower amount of LH induced by GnRH agonist.

      Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG)
      for preventing OHSS and maintaining clinical outcome in high risk patients who receive
      controlled ovarian stimulation in GnRH antagonist protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>clinical pregnancy rate per transfer cycle</measure>
    <time_frame>1month post embryo transfer</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>numbers of patients having OHSS</measure>
    <time_frame>2 weeks post trigger with dual GnRHa</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>oocyte yield</measure>
    <time_frame>oocyte retrieval day (34 to 38 hours post trigger with GnRHa and hCG)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Oocyte yield was defined as the ratio of the total number of collected oocytes to the number of follicles measuring â‰¥10 mm on the day of oocyte retrieval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oocyte maturity</measure>
    <time_frame>24 hours post oocyte retrieval day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Oocyte maturity was defined as the ratio of metaphase II (MII) oocytes to the number of collected oocytes in the patients undergoing with intracytoplasmic sperm injection (ICSI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum luteinizing hormone level 12 hours post trigger</measure>
    <time_frame>12 hours post trigger</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum hCG level 12 hours post trigger</measure>
    <time_frame>12 hours post trigger</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>48 hours post IVF/ICSI</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Fertilization rate was defined as the ratio of normal fertilized oocytes (2PNs) to the number of oocytes used for fertilization (i.e. the denominator in IVF in calculating fertilization rate is all oocytes recovered, but in ICSI it is calculated using only the number of MII oocytes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>1 month post embryo transfer</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility and at High Risk of OHSS</condition>
  <arm_group>
    <arm_group_label>0.2mg triptorelin and 500 IU hCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were triggered with 0.2mg triptorelin and 500 IU hCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2mg triptorelin and 1000 IU hCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were triggered with 0.2mg triptorelin and 1000 IU hCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
    <description>0.2 mg triptorelin, ih</description>
    <arm_group_label>0.2mg triptorelin and 500 IU hCG</arm_group_label>
    <arm_group_label>0.2mg triptorelin and 1000 IU hCG</arm_group_label>
    <other_name>triptorelin: Diphereline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>1000 IU hCG, im</description>
    <arm_group_label>0.2mg triptorelin and 1000 IU hCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>500IU hCG, im</description>
    <arm_group_label>0.2mg triptorelin and 500 IU hCG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with polycystic ovarian syndrome

          -  patients with polycystic ovarian morphology on ultrasound

          -  patients who previously experienced an ovarian stimulation cycle, with a high
             response to gonadotrophins

        Exclusion Criteria:

          -  patients undergoing coasting

          -  patients with past ovarian surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shi-Ling Chen, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shi-Ling Chen, M.D., Ph.D.</last_name>
    <phone>+86-20-62787604</phone>
    <email>chensl_92@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shi-Ling Chen, M.D., Ph.D.</last_name>
      <phone>+86-20-62787604</phone>
      <email>chensl_92@163.com</email>
    </contact>
    <investigator>
      <last_name>Shi-Ling Chen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>December 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Chenshiling</investigator_full_name>
    <investigator_title>Professor, M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Ovarian Hyperstimulation Syndrome</keyword>
  <keyword>Luteinizing Hormone</keyword>
  <keyword>Polycystic Ovarian Syndrome</keyword>
  <keyword>Ovarian Yield</keyword>
  <keyword>Ovarian Maturity</keyword>
  <keyword>Gonadotropin Releasing Hormone Agonist</keyword>
  <keyword>Human Chorionic Gonadotropin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Triptorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
